EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance

Nan Zhou iD, Jaewoo Choi, Grant Grothusen iD, Bang-Jin Kim, Diqiu Ren, Zhendong Cao, Yiman Liu, Qinglan Li, Arati Inamdar iD, Thomas Beer, Hsin-Yao Tang, Eric Perkey und 6 weitere

Blood · 2023

DOI: 10.1182/blood.2022018752 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Nan Zhou und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Up to 40% of patients with DLBCL display refractory disease or relapse after standard chemotherapy treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), leading to significant morbidity and mortality. The molecular mechanisms of chemoresistance in DLBCL remain incompletely understood. Using a cullin–really interesting new gene (RING) ligase-based CRISPR-Cas9 library, we identify that inactivation of the E3 ubiquitin ligase KLHL6 promotes DLBCL chemoresistance. Furthermore, proteomic approaches helped identify KLHL6 as a novel master regulator of plasma membrane–associated NOTCH2 via proteasome-dependent degradation. In CHOP-resistant DLBCL tumors, mutations of NOTCH2 result in a protein that escapes the mechanism of ubiquitin-dependent proteolysis, leading to protein stabilization and activation of the oncogenic RAS signaling pathway. Targeting CHOP-resistant DLBCL tumors with the phase 3 clinical trial molecules nirogacestat, a selective γ-secretase inhibitor, and ipatasertib, a pan-AKT inhibitor, synergistically promotes DLBCL destruction. These findings establish the rationale for therapeutic strategies aimed at targeting the oncogenic pathway activated in KLHL6- or NOTCH2-mutated DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmLymphoma, Large B-Cell, DiffuseHumansUbiquitinProteomicsNeoplasm Recurrence, LocalRituximabVincristineCyclophosphamideDoxorubicinPrednisoneMutationAntineoplastic Combined Chemotherapy ProtocolsReceptor, Notch2

Substanzen

UbiquitinRituximabVincristineCyclophosphamideDoxorubicinPrednisoneNOTCH2 protein, humanReceptor, Notch2

Autor:innen und Institutionen

  • Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Department of Surgery, Columbia University Irving Medical Center, New York, NY.
  • Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Proteomics and Metabolomics Facility, The Wistar Institute, Philadelphia, PA.
  • Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Epigenetics Institute and Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Nan Zhou, Grant Grothusen, Arati Inamdar, Ivan Maillard, Roberto Bonasio, Junwei Shi, Marco Ruella

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NHGRI NIH HHS

Zitieren

APA

Zhou, N., Choi, J., Grothusen, G., Kim, B. J., Ren, D., Cao, Z., Liu, Y., Li, Q., Inamdar, A., Beer, T., Tang, H. Y., Perkey, E., Maillard, I., Bonasio, R., Shi, J., Ruella, M., Wan, L., & Busino, L. (2023). DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood. https://doi.org/10.1182/blood.2022018752

Vancouver

Zhou N, Choi J, Grothusen G, Kim BJ, Ren D, Cao Z, et al. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance. Blood. 2023. doi:10.1182/blood.2022018752

BibTeX
@article{Zhou2023,
  author = {Zhou, Nan and Choi, Jaewoo and Grothusen, Grant and Kim, Bang-Jin and Ren, Diqiu and Cao, Zhendong and Liu, Yiman and Li, Qinglan and Inamdar, Arati and Beer, Thomas and Tang, Hsin-Yao and Perkey, Eric and Maillard, Ivan and Bonasio, Roberto and Shi, Junwei and Ruella, Marco and Wan, Liling and Busino, Luca},
  title = {DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018752}
}
Kostenlos starten →